is it safe to switch from tirzepatide to semaglutide Switching GLP-1 Agonists for MAXIMUM Weightloss Transitioning Treatments: What to Expect

This was followed by a 38-day pharmacokinetic blood sampling and safety assessment period (i.e., 45 times the estimated cagrilintide t 1/2 ), with blood samples collected on days 8, 15, 22, 29 and 39

Seventh, our primary efficacy analyses targeted an on-treatment estimand and, therefore, may overestimate effectiveness compared with a treatment-policy (all-exposed) approach

The trial ran for 96 weeks and was double blind, meaning that neither the participants nor researchers knew who was receiving the real treatment or placebo

BGX does not guarantee customs release and is not responsible for delays, seizure, refusal, return, or destruction by customs or another authority except where applicable law provides otherwise